GlassScriptPhysician profile
Robin M Brammer
NPI 1275575995
$3,274.62
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $862 · 2020: $674 · 2021: $1,412 · 2022: $326.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $860.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $636.53 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $294.20 | 2019-2022 | |
| Lilly USA, LLC | $275.84 | 2019-2022 | |
| Mylan Specialty L.P. | $265.61 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $128.15 | 2019-2021 | |
| Optinose US, INC. | $86.14 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $75.41 | 2019-2021 | |
| Philips North America LLC | $73.62 | 2019-2022 | |
| Advanced Respiratory, INC | $58.76 | 2020-2021 | |
| Electromed, INC. | $57.74 | 2019-2022 | |
| Pfizer INC. | $57.22 | 2021 | |
| Vanda Pharmaceuticals INC. | $50.46 | 2020 | |
| Eisai INC. | $47.40 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $42.38 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.73 | 2019-2020 | |
| Genzyme Corporation | $41.23 | 2021 | |
| Harmony Biosciences LLC | $32.20 | 2021 | |
| Circassia INC. | $23.06 | 2019 | |
| Shire North American Group INC | $21.82 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.88 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.99 | 2021 | |
| Pharming Healthcare, INC. | $14.83 | 2021 | |
| Genentech USA, INC. | $14.05 | 2019 | |
| Allergan, INC. | $13.94 | 2020 | |
| Endo Pharmaceuticals INC. | $12.91 | 2020 | |
| Abbvie INC. | $11.70 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Brammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.